AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JAN 1 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - An intranasal vaccine developed with an retro-inverso analogue of the influenza virus hemagglutinin B-cell epitope protected mice against serious influenza disease, according to a report in the journal Molecular Immunology.
"Retro-inverso peptides are composed of D-amino acids assembled in a reverse order from that of the parent L-sequence, thus maintaining the overall topology of the native sequence," explained Tamar Ben-Yedidia and colleagues at The Weizmann Institute of Science in Israel and the Institut de Biologie Moleculaire et Cellulaire in France. "We investigated the possibility of replacing an all-L amino acid peptide sequence corresponding to the protective B-cell epitope hemagglutinin (HA) 91-108 from influenza HA with a retro-inverso analogue encompassing this sequence."
The investigators conjugated the HA retro-inverso analogue to ovalbumin and administered it, with cholera toxin as an adjuvant, intranasally to mice.
The vaccine elicited potent IgA and IgG antibody responses in the mice. Vaccinated mice that were challenged intranasally with a potentially lethal dose of influenza virus developed a mild form of influenza from which they quickly recovered.
The secretion of high levels of gamma interferon (IFN-gamma) could be stimulated by culturing the splenocytes of vaccinated mice in the presence of inactivated influenza virus. In addition, the retro-inverso analogue was significantly more resistant to lung protease action ...
Source: HighBeam Research, Retro-inverso peptide technology used to develop vaccine against...